Advanced Solid Malignancies

17
Pipeline Programs
9
Companies
18
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
14
2
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 16 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
9 programs
8
1
MEDI4736Phase 31 trial
AZD1208Phase 11 trial
AZD2014Phase 11 trial
AZD2014Phase 11 trial
AZD4635Phase 11 trial
+4 more programs
Active Trials
NCT01588548Completed43Est. Jul 2014
NCT01026402Completed172Est. Aug 2014
NCT02398747Completed28Est. Apr 2024
+6 more trials
Treadwell Therapeutics
1 program
1
CFI-402411Phase 1/21 trial
Active Trials
NCT04521413Active Not RecruitingEst. Dec 2025
Carrick Therapeutics
Carrick TherapeuticsIreland - Dublin
1 program
1
CT7001Phase 1/21 trial
Active Trials
NCT03363893CompletedEst. Dec 2022
BioCity Biopharma
BioCity BiopharmaChina - Wuxi
1 program
1
BC2027 for InjectionPhase 11 trial
Active Trials
NCT07368478RecruitingEst. Jun 2028
Bristol Myers Squibb
1 program
1
BMS-663513Phase 11 trial
Active Trials
NCT00351325Terminated45Est. Mar 2009
Novartis
NovartisBASEL, Switzerland
1 program
1
HSP990Phase 11 trial
Active Trials
NCT00879905Completed64Est. Jul 2012
Takeda
TakedaTOKYO, Japan
1 program
1
MLN0128Phase 13 trials
Active Trials
NCT02724020Completed96Est. Oct 2020
NCT01351350Completed68Est. Sep 2017
NCT01058707Completed198Est. Feb 2019
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
REGN421Phase 1
GSK
GSKLONDON, United Kingdom
1 program
1
TopotecanPhase 11 trial
Active Trials
NCT00295243Completed25Est. Nov 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
AstraZenecaMEDI4736
TakedaMLN0128
Treadwell TherapeuticsCFI-402411
Carrick TherapeuticsCT7001
BioCity BiopharmaBC2027 for Injection
AstraZenecaAZD5305
AstraZenecaCeralasertib
AstraZenecaAZD4635
AstraZenecaMEDI9447
AstraZenecaAZD2014
AstraZenecaAZD1208
TakedaMLN0128
AstraZenecaMEDI-575
TakedaMLN0128
AstraZenecaAZD2014

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 1,672 patients across 18 trials

NCT03084471AstraZenecaMEDI4736

An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

Start: Jun 2017Est. completion: Dec 2022867 patients
Phase 3Completed
NCT02724020TakedaMLN0128

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Start: Jun 2016Est. completion: Oct 202096 patients
Phase 2Completed
NCT04521413Treadwell TherapeuticsCFI-402411

Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies

Start: Aug 2020Est. completion: Dec 2025
Phase 1/2Active Not Recruiting
NCT03363893Carrick TherapeuticsCT7001

Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies

Start: Nov 2017Est. completion: Dec 2022
Phase 1/2Completed
NCT07368478BioCity BiopharmaBC2027 for Injection

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies

Start: Nov 2025Est. completion: Jun 2028
Phase 1Recruiting
NCT05573724AstraZenecaAZD5305

Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies

Start: Nov 2022Est. completion: May 202416 patients
Phase 1Completed
NCT05469919AstraZenecaCeralasertib

An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies

Start: Jun 2022Est. completion: Mar 202412 patients
Phase 1Completed
NCT03980821AstraZenecaAZD4635

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

Start: Jul 2019Est. completion: Sep 202010 patients
Phase 1Completed
NCT03736473AstraZenecaMEDI9447

A Phase I Study of MEDI9447 (Oleclumab) in Japanese Patients

Start: Nov 2018Est. completion: Jun 20196 patients
Phase 1Completed
NCT02398747AstraZenecaAZD2014

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Start: Mar 2015Est. completion: Apr 202428 patients
Phase 1Completed
NCT01588548AstraZenecaAZD1208

Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma

Start: Jul 2012Est. completion: Jul 201443 patients
Phase 1Completed
NCT01351350TakedaMLN0128

Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies

Start: Feb 2011Est. completion: Sep 201768 patients
Phase 1Completed
NCT01102400AstraZenecaMEDI-575

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Start: Mar 2010Est. completion: Nov 201222 patients
Phase 1Completed
NCT01058707TakedaMLN0128

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

Start: Jan 2010Est. completion: Feb 2019198 patients
Phase 1Completed
NCT01026402AstraZenecaAZD2014

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Start: Dec 2009Est. completion: Aug 2014172 patients
Phase 1Completed
NCT00879905NovartisHSP990

A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Start: May 2009Est. completion: Jul 201264 patients
Phase 1Completed
NCT00351325Bristol Myers SquibbBMS-663513

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Start: Sep 2007Est. completion: Mar 200945 patients
Phase 1Terminated
NCT00295243GSKTopotecan

Phase I Study of GW572016 With Topotecan to Treat Advanced Solid Malignancies

Start: Sep 2004Est. completion: Nov 200625 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 1,672 patients
9 companies competing in this space